scholarly journals A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum

Medicine ◽  
2022 ◽  
Vol 101 (2) ◽  
pp. e28585
2020 ◽  
Vol 25 (9) ◽  
Author(s):  
Aleksei Viktorovich Novik ◽  
Anna Borisovna Danilova ◽  
Maksim Ivanovich Sluzhev ◽  
Tatiana Leonidovna Nehaeva ◽  
Sergei Sergeevich Larin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document